Risk factor
Moderate default risk
Profitability factor
Overvalued vs peers
About
Bachem Holding AG provides essential products to pharmaceutical and biotechnology companies worldwide, supporting their activities from early research and clinical trials through to commercial manufacturing. The company's primary focus is on the development, production, and regulatory assistance for peptide active pharmaceutical ingredients (APIs), particularly novel peptide and oligonucleotide compounds. Additionally, Bachem offers commercial-grade new chemical entities (NCEs) and generic APIs, complemented by services including project management, quality assurance, regulatory guidance, analytical testing, Good Manufacturing Practice (GMP) compliant production, research-grade material manufacturing, and integrated supply chain solutions. Established in 1971, this Swiss company is headquartered in Bubendorf and operates as a subsidiary of Ingro Finanz AG.
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.